Ovid’s 7 mg OV329 cohort demonstrated favorable safety and tolerability in both single and multiple ascending dose cohorts, with no treatment-related adverse events and only mild, transient unrelated events in 19 instances. These findings reinforce OV329’s best-in-category profile for drug-resistant epilepsies and support dose selection for planned patient studies.

The company plans to expand OV329 development into tuberous sclerosis complex seizures and infantile spasms, two rare epileptic disorders with high unmet need. This effort is funded by a $60.0 million private placement, which will underwrite complementary indication trials alongside focal onset seizure studies.

OV4071, a first-in-class oral KCC2 activator, received Human Research Ethics Committee approval and Therapeutic Goods Administration acknowledgment of its Clinical Trial Notification. This clearance triggers a 30-day exercise period for outstanding Series A warrants and paves the way for initiating a Phase 1 trial in Australia.

As of December 31, 2025, Ovid held $90.4 million in cash, cash equivalents and marketable securities, expected to fund key studies through late 2028, with warrant exercises potentially extending the runway into 2029. The company will host a KCC2-focused R&D Day on April 14, 2026 and a business update call today at 8:30 am ET.